|Day Low/High||103.64 / 104.95|
|52 Wk Low/High||75.81 / 106.74|
FDA Approval Triggers $15 Million Payment
The young adults, each affected by a bleeding disorder, will perform in the Broadway-style musical upon completion of the 'Breaking Through!' Musical Theater Intensive workshop
Company listed amongst top five biotech employers
Cantor Fitzgerald Global Healthcare Conference on October 1 in New York City
Updated results from Phase 1/2 program for tralesinidase alfa (formerly BMN 250)
- Citi's 13th Annual Biotech Conference on September 5-6 in Boston
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ASPS, BMRN, CNHI, GTIM, JHX, NXEOU, PICO, USAP, VTSI, WUBA Downgrades: ABCB, CTRP, FDP, GBLI, MHLD, PDLI, SMCI, TV Initiations: BHF, PLXP Read on to get TheStreet Quant Ratings' detailed report:
Follow the experts. These biotech stocks have Wall Street's best analysts getting bullish.
It is all about perception, and here are strong names to pick up on market weakness.
I have not seen a bullish breakout from a large base pattern in a while.
Here's how BMRN's chart looks after its blistering gains.
SAN RAFAEL, Calif., July 11, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc.
First-of-Its-Kind Musical to Help Empower the Bleeding Disorder Community to Find and Use their Voices through the Power of Music
Five Students with Rare Genetic Diseases Receive a Total of $20,000 for Higher Education
SAN RAFAEL, Calif., June 14, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., June 7, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc.
The upswing is welcomed but it still is not an important breakout of the two-year sideways pattern.
Take one part great earnings and one part tremendous skepticism, add in low inflation and you end up with this astonishing stealth rally. Jim Cramer explains it.
Since taking office, President Trump has talked big on reining in drug prices, but the administration's lack of action leaves most expecting a May 11 speech that tastes like a nothing burger.
Jim Cramer and our other experts discus China and tariffs, the 10 year nearing 3%, technical analysis, and biotech stocks.
I think M&A activity will pick up markedly going forward across the industry.
Here's what you need to know for Monday, April 9.
While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.
These five 'Strong Buy' stocks boast a double whammy of only buy ratings and big upside potential. After the market's recent plunge, this list is quite handy.
I do not need to come up with any grand arguments for a bullish or bearish bias. It happens by default.
Here are how some of the conference presenters are performing on the market Wednesday
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.